Published in Vaccine Weekly, July 13th, 2005
According to recent research from China, "Alzheimer disease (AD) is a neurodegenerative disorder characterized by overproduction of beta-amylold (A-beta), with the subsequent pathologic deposition of A-beta which is important for memory and cognition.
"Recent studies showed murine models of AD and AD patients inoculated with A-beta peptide vaccine had a halted or delayed pathological progression of AD. Unfortunately, the clinical phase IIa trial of A-beta(1-42) peptide vaccine (AN1792) was halted...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
Source: Vaccine Weekly (2005-07-13)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.